View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Oscar Haffen Lamm
  • Oscar Haffen Lamm

Cinclus: reaches agreement with the EMA on the PIP

Cinclus Pharma has secured an agreement with the EMA Paediatric Committee (PDCO) on their Paediatric Investigation Plan (PIP) for linaprazan glurate, a necessary step toward obtaining marketing approval for adult use in the EU. A PIP outlines the approach for studying new medications in paediatric

Oscar Haffen Lamm
  • Oscar Haffen Lamm

Cinclus: Q2 reiterated phase 3 trial timeline

Cinclus Pharma reported its Q2'24 results with a cash position at SEK 684.72m and an EBIT at SEK (37.329m). On the operations side, it has been reiterated that i) the company is looking to enroll the first patient in the 1st phase 3 study in 2025, with a readout expected in 2026, and ii) its Chines

Oscar Haffen Lamm
  • Oscar Haffen Lamm

Cinclus: Positive read-x, US market showing growing interest in PCABs

Phathom Pharma reported its Q2 report yesterday, which highlighted a positive launch of its 1st generation PCAB Voquezna (vonoprazan), where filled prescriptions amounted 35,000 (+265% QoQ) for the quarter, with 77% of total US commercial lives covered. We are encouraged by such a positive launch t

Oscar Haffen Lamm
  • Oscar Haffen Lamm

Better, faster, stronger! Taking on the eGERD market

Cinclus Pharma is a Swedish late-stage biopharmaceutical company developing a proprietary drug candidate, linaprazan glurate (LG), a next generation and potential best-in-class Potassium Competitive Acid Blocker (PCAB), which is a fast-acting regulator of intragastric pH by a different MoA than PPI

New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch